Patient longevity and survival with custom-made endovascular solutions: The Fenestrated Anaconda TM approach

Endovascular aortic repair (EVAR) has become the mainstay treatment for abdominal aortic aneurysms and is associated with excellent clinical outcomes. However, there remains a risk of complications requiring reintervention. Several EVAR devices exist commercially, yet, the Terumo Aortic Fenestrated...

Full description

Saved in:
Bibliographic Details
Published in:Asian cardiovascular & thoracic annals 2023-02, p.2184923231158579
Main Authors: Jubouri, Matti, Surkhi, Abdelaziz O, Tan, Sven Z C P, Bailey, Damian M, Williams, Ian M
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page 2184923231158579
container_title Asian cardiovascular & thoracic annals
container_volume
creator Jubouri, Matti
Surkhi, Abdelaziz O
Tan, Sven Z C P
Bailey, Damian M
Williams, Ian M
description Endovascular aortic repair (EVAR) has become the mainstay treatment for abdominal aortic aneurysms and is associated with excellent clinical outcomes. However, there remains a risk of complications requiring reintervention. Several EVAR devices exist commercially, yet, the Terumo Aortic Fenestrated Anaconda™ has demonstrated outstanding results. The main scope of this study is to evaluate survival/longevity, target vessel patency (TVP), endograft migration and reintervention following Fenestrated Anaconda™ implantation and discuss relevant literature. The current study represents a 9-year cross-sectional international analysis of custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R was utilised. Pearson Chi-Square analysis was used to assess differences in cumulative distribution frequencies between variables. Statistical significance for all two-tailed tests was set at  
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_36803010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36803010</sourcerecordid><originalsourceid>FETCH-pubmed_primary_368030103</originalsourceid><addsrcrecordid>eNqFzr0KwjAUQOEgiP-vIPcFCilBLW4iFhfBobtcm6uNpEnJTSp9exednc7yDWckZnmRb7ON2smpmDO_pJQqV8VETNW2kErmcibsFaMhF8F696TexAHQaeAUetOjhbeJDdSJo2-zFjUBOe175DpZDMDepmi84z1UDUFJjjgGjKTh4LD2TiNUF8CuCx7rZinGD7RMq28XYl2equM569K9JX3rgmkxDLffnvoLPhiCR0Q</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Patient longevity and survival with custom-made endovascular solutions: The Fenestrated Anaconda TM approach</title><source>Sage Journals Online</source><creator>Jubouri, Matti ; Surkhi, Abdelaziz O ; Tan, Sven Z C P ; Bailey, Damian M ; Williams, Ian M</creator><creatorcontrib>Jubouri, Matti ; Surkhi, Abdelaziz O ; Tan, Sven Z C P ; Bailey, Damian M ; Williams, Ian M</creatorcontrib><description>Endovascular aortic repair (EVAR) has become the mainstay treatment for abdominal aortic aneurysms and is associated with excellent clinical outcomes. However, there remains a risk of complications requiring reintervention. Several EVAR devices exist commercially, yet, the Terumo Aortic Fenestrated Anaconda™ has demonstrated outstanding results. The main scope of this study is to evaluate survival/longevity, target vessel patency (TVP), endograft migration and reintervention following Fenestrated Anaconda™ implantation and discuss relevant literature. The current study represents a 9-year cross-sectional international analysis of custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R was utilised. Pearson Chi-Square analysis was used to assess differences in cumulative distribution frequencies between variables. Statistical significance for all two-tailed tests was set at  &lt; 0.05. A total of 5058 patients received the Fenestrated Anaconda™ endograft. The Fenestrated Anaconda™ was indicated either due to complex anatomy for competitor devices (  = 3891, 76.9%) or based on surgeon preference (  = 1167, 23.1%). Both survival and TVP were 100% during the first 6 postoperative years but dropped to 77.1% and 81% thereafter. In the complex anatomy indication group, cumulative survival and TVP were both 100% until year 7 post-EVAR when they decreased to 82.8% and 75.7%. In the other indication group, survival and TVP were also 100% during the first 6 years but plateaued at 58.1% and 98.8% in years 7-9 of follow-up. No cases of endograft migration and reintervention were recorded. The Fenestrated Anaconda™ has been proven across the literature to be a highly effective EVAR endograft, as it has demonstrated excellent survival/longevity and TVP as well as minimal endograft migration and reintervention.</description><identifier>EISSN: 1816-5370</identifier><identifier>PMID: 36803010</identifier><language>eng</language><publisher>England</publisher><ispartof>Asian cardiovascular &amp; thoracic annals, 2023-02, p.2184923231158579</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-1145-107X ; 0000-0001-6725-6164 ; 0000-0001-8676-3778</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36803010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jubouri, Matti</creatorcontrib><creatorcontrib>Surkhi, Abdelaziz O</creatorcontrib><creatorcontrib>Tan, Sven Z C P</creatorcontrib><creatorcontrib>Bailey, Damian M</creatorcontrib><creatorcontrib>Williams, Ian M</creatorcontrib><title>Patient longevity and survival with custom-made endovascular solutions: The Fenestrated Anaconda TM approach</title><title>Asian cardiovascular &amp; thoracic annals</title><addtitle>Asian Cardiovasc Thorac Ann</addtitle><description>Endovascular aortic repair (EVAR) has become the mainstay treatment for abdominal aortic aneurysms and is associated with excellent clinical outcomes. However, there remains a risk of complications requiring reintervention. Several EVAR devices exist commercially, yet, the Terumo Aortic Fenestrated Anaconda™ has demonstrated outstanding results. The main scope of this study is to evaluate survival/longevity, target vessel patency (TVP), endograft migration and reintervention following Fenestrated Anaconda™ implantation and discuss relevant literature. The current study represents a 9-year cross-sectional international analysis of custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R was utilised. Pearson Chi-Square analysis was used to assess differences in cumulative distribution frequencies between variables. Statistical significance for all two-tailed tests was set at  &lt; 0.05. A total of 5058 patients received the Fenestrated Anaconda™ endograft. The Fenestrated Anaconda™ was indicated either due to complex anatomy for competitor devices (  = 3891, 76.9%) or based on surgeon preference (  = 1167, 23.1%). Both survival and TVP were 100% during the first 6 postoperative years but dropped to 77.1% and 81% thereafter. In the complex anatomy indication group, cumulative survival and TVP were both 100% until year 7 post-EVAR when they decreased to 82.8% and 75.7%. In the other indication group, survival and TVP were also 100% during the first 6 years but plateaued at 58.1% and 98.8% in years 7-9 of follow-up. No cases of endograft migration and reintervention were recorded. The Fenestrated Anaconda™ has been proven across the literature to be a highly effective EVAR endograft, as it has demonstrated excellent survival/longevity and TVP as well as minimal endograft migration and reintervention.</description><issn>1816-5370</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFzr0KwjAUQOEgiP-vIPcFCilBLW4iFhfBobtcm6uNpEnJTSp9exednc7yDWckZnmRb7ON2smpmDO_pJQqV8VETNW2kErmcibsFaMhF8F696TexAHQaeAUetOjhbeJDdSJo2-zFjUBOe175DpZDMDepmi84z1UDUFJjjgGjKTh4LD2TiNUF8CuCx7rZinGD7RMq28XYl2equM569K9JX3rgmkxDLffnvoLPhiCR0Q</recordid><startdate>20230220</startdate><enddate>20230220</enddate><creator>Jubouri, Matti</creator><creator>Surkhi, Abdelaziz O</creator><creator>Tan, Sven Z C P</creator><creator>Bailey, Damian M</creator><creator>Williams, Ian M</creator><scope>NPM</scope><orcidid>https://orcid.org/0000-0003-1145-107X</orcidid><orcidid>https://orcid.org/0000-0001-6725-6164</orcidid><orcidid>https://orcid.org/0000-0001-8676-3778</orcidid></search><sort><creationdate>20230220</creationdate><title>Patient longevity and survival with custom-made endovascular solutions: The Fenestrated Anaconda TM approach</title><author>Jubouri, Matti ; Surkhi, Abdelaziz O ; Tan, Sven Z C P ; Bailey, Damian M ; Williams, Ian M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_368030103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Jubouri, Matti</creatorcontrib><creatorcontrib>Surkhi, Abdelaziz O</creatorcontrib><creatorcontrib>Tan, Sven Z C P</creatorcontrib><creatorcontrib>Bailey, Damian M</creatorcontrib><creatorcontrib>Williams, Ian M</creatorcontrib><collection>PubMed</collection><jtitle>Asian cardiovascular &amp; thoracic annals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jubouri, Matti</au><au>Surkhi, Abdelaziz O</au><au>Tan, Sven Z C P</au><au>Bailey, Damian M</au><au>Williams, Ian M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient longevity and survival with custom-made endovascular solutions: The Fenestrated Anaconda TM approach</atitle><jtitle>Asian cardiovascular &amp; thoracic annals</jtitle><addtitle>Asian Cardiovasc Thorac Ann</addtitle><date>2023-02-20</date><risdate>2023</risdate><spage>2184923231158579</spage><pages>2184923231158579-</pages><eissn>1816-5370</eissn><abstract>Endovascular aortic repair (EVAR) has become the mainstay treatment for abdominal aortic aneurysms and is associated with excellent clinical outcomes. However, there remains a risk of complications requiring reintervention. Several EVAR devices exist commercially, yet, the Terumo Aortic Fenestrated Anaconda™ has demonstrated outstanding results. The main scope of this study is to evaluate survival/longevity, target vessel patency (TVP), endograft migration and reintervention following Fenestrated Anaconda™ implantation and discuss relevant literature. The current study represents a 9-year cross-sectional international analysis of custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R was utilised. Pearson Chi-Square analysis was used to assess differences in cumulative distribution frequencies between variables. Statistical significance for all two-tailed tests was set at  &lt; 0.05. A total of 5058 patients received the Fenestrated Anaconda™ endograft. The Fenestrated Anaconda™ was indicated either due to complex anatomy for competitor devices (  = 3891, 76.9%) or based on surgeon preference (  = 1167, 23.1%). Both survival and TVP were 100% during the first 6 postoperative years but dropped to 77.1% and 81% thereafter. In the complex anatomy indication group, cumulative survival and TVP were both 100% until year 7 post-EVAR when they decreased to 82.8% and 75.7%. In the other indication group, survival and TVP were also 100% during the first 6 years but plateaued at 58.1% and 98.8% in years 7-9 of follow-up. No cases of endograft migration and reintervention were recorded. The Fenestrated Anaconda™ has been proven across the literature to be a highly effective EVAR endograft, as it has demonstrated excellent survival/longevity and TVP as well as minimal endograft migration and reintervention.</abstract><cop>England</cop><pmid>36803010</pmid><orcidid>https://orcid.org/0000-0003-1145-107X</orcidid><orcidid>https://orcid.org/0000-0001-6725-6164</orcidid><orcidid>https://orcid.org/0000-0001-8676-3778</orcidid></addata></record>
fulltext fulltext
identifier EISSN: 1816-5370
ispartof Asian cardiovascular & thoracic annals, 2023-02, p.2184923231158579
issn 1816-5370
language eng
recordid cdi_pubmed_primary_36803010
source Sage Journals Online
title Patient longevity and survival with custom-made endovascular solutions: The Fenestrated Anaconda TM approach
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A06%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient%20longevity%20and%20survival%20with%20custom-made%20endovascular%20solutions:%20The%20Fenestrated%20Anaconda%20TM%20approach&rft.jtitle=Asian%20cardiovascular%20&%20thoracic%20annals&rft.au=Jubouri,%20Matti&rft.date=2023-02-20&rft.spage=2184923231158579&rft.pages=2184923231158579-&rft.eissn=1816-5370&rft_id=info:doi/&rft_dat=%3Cpubmed%3E36803010%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-pubmed_primary_368030103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/36803010&rfr_iscdi=true